SK Biopharmaceuticals acquired exclusive worldwide rights from the Wisconsin Alumni Research Foundation (WARF) to develop, manufacture and commercialize WT‑7695, a preclinical radiopharmaceutical developed with the University of Wisconsin‑Madison. The licensing deal gives SK Biopharma control of a targeted radiotherapeutic candidate as it expands its oncology portfolio into radiopharma, with rights to advance IND‑enabling studies, CMC scale‑up and global regulatory filings.